Jump to content

Sumitomo Pharma

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Benstown (talk | contribs) at 06:00, 28 September 2018 (svg logo). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Sumitomo Dainippon Pharma Co., Ltd.
Company typePublic KK
TYO: 4506
IndustryBiotech & Pharmaceuticals
Predecessor
  • Dainippon Pharmaceutical
  • Sumitomo Pharmaceuticals
FoundedOctober 1, 2005 (merger of Dainippon Pharmaceutical & Sumitomo Pharmaceuticals)
Headquarters6-8, Doshomachi 2-chome, Chuo-ku, Osaka, Osaka 541-0045, Japan
Key people
Masayo Tada, (President and CEO)
Products
RevenueIncrease US$ 3.76 billion (FY 2013) (¥ 387.69 billion) (FY 2013)
Increase US$ 194.94 million (FY 2013) (¥ 20.06 billion) (FY 2013)
Number of employees
7,009 (consolidated)
4,291 (non-consolidated) (as of June 30, 2014)
WebsiteOfficial website
Footnotes / references
[1][2][3][4]

Sumitomo Dainippon Pharma Co., Ltd. (大日本住友製薬株式会社, Dainippon Sumitomo Seiyaku Kabushiki-Gaisha) is a pharmaceutical company based in Japan. Its headquarters are in Chuo-ku, Osaka.[5]

The original Dainippon Pharmaceuticals (Dainippon Seiyaku) was established in 1885 by Nagayo Sensai, a graduate of Tekijuku – the first private medical school in Japan established by Ogata Kōan. It was set up as a wholly private company invested by a number of people in Tokyo and Osaka, with the land and buildings let by the government. Technical expertise for the enterprise was provided by Shibata Shokei and Nagai Nagayoshi, who were also among the first students trained abroad at government expense.

The company started its operation in 1885 with equipment imported from Germany. The main products were tincture and other similar drugs listed in the Japanese Pharmacopoeia. Among them was ephedrine, an anti-asthma drug invented by Nagai. In 1893, however, Nagai left the company and the business started to make a loss. in 1898 it was acquired by Osaka Seiyaku (Osaka Pharmaceutical).[6]

Another origin of the company is Sumitomo Pharmaceuticals, incorporated in 1984 as a subsidiary of Sumitomo Chemical (holding 77.83% of the share as of 2006).[7] Dainippon and Sumitomo merged on October 1, 2005 to create Dainippon Sumitomo Pharma.[8] As a result, Sumitomo Chemical has 50.20% ownership in Dainippon Sumitomo Pharma as of March 31, 2014.[2]

Head office in Osaka

Sunovion

Sunovion (formerly Sepracor Inc.), was acquired by Sumitomo Dainippon in 2010,[9] is a subsidiary now based in Marlborough, Massachusetts, USA.

In September 2016, the Sunovion announced it would acquire Cynapsus Therapeutics for approximately $624 million, specifically expanding Sunovion's central nervous system drug portfolio. Through the deal, Sunovion would acquire Cynapsus’ Phase III Parkinson’s disease candidate drug APL-130277,[10] a sublingual formulation of Apomorphine.[11]

References

  1. ^ "Corporate Profile". Dainippon Sumitomo Pharma. Retrieved September 13, 2014.
  2. ^ a b "Fact Book 2014" (PDF). Dainippon Sumitomo Pharma. Retrieved November 3, 2011.
  3. ^ "Company Snapshot". Bloomberg Businessweek. Retrieved September 13, 2014.
  4. ^ "Company Profile". Bloomberg L.P. Retrieved September 13, 2014.
  5. ^ "Company Summary". Google Finance. Retrieved September 13, 2014.
  6. ^ Odagiri, Hiroyuki (1996). Technology and Industrial Development in Japan. Clarendon Press, Oxford. p. 239. ISBN 0-19-828802-6.
  7. ^ 連結子会社の合併に関するお知らせ (PDF) (in Japanese). Sumitomo Chemical. November 25, 2004. Retrieved November 3, 2011.
  8. ^ "Corporate History". Dainippon Sumitomo Pharma. Retrieved November 3, 2011.
  9. ^ Company press release
  10. ^ "Sunovion to Acquire Cynapsus for $624M - GEN News Highlights - GEN".
  11. ^ https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=1343
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sumitomo_Pharma&oldid=861543169"